Update on systemic treatment in early triple negative breast cancer

被引：29

作者：

Nunez Abad, Martin ^{[1
]}

Calabuig-Farinas, Silvia ^{[2
,4
,5
,6
,7
]}

Lobo de Mena, Miriam ^{[1
]}

Sanz de Bremond, Maria Jose Godes ^{[1
]}

Garcia Gonzalez, Clara ^{[1
]}

Torres Martinez, Susana ^{[2
,4
]}

Angel Garcia-Garcia, Jose ^{[8
]}

Iranzo Gonzalez-Cruz, Vega ^{[1
,2
,3
]}

Camps Herrero, Carlos ^{[1
,2
,4
,6
,7
]}

机构：

[1] Univ Gen Hosp Valencia, Dept Med Oncol, Tres Cruces 2, Valencia 46014, Spain

[2] CIBERONC, Madrid, Spain

[3] Univ Valencia, Dept Med, Valencia, Spain

[4] Univ Gen Hosp Valencia, Gen Univ Hosp Res Fdn, Mol Oncol Lab, Valencia, Spain

[5] Univ Valencia, Dept Pathol, Valencia, Spain

[6] Principe Felipe Res Ctr, Mixed Unit TRIAL, Valencia, Spain

[7] Gen Univ Hosp Valencia Res Fdn, Valencia, Spain

[8] Univ Gen Hosp Valencia, Dept Pathol Anat, Valencia, Spain

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2021年 / 13卷

关键词：

chemotherapy; immunotherapy; neoadjuvant therapy; precision medicine; systemic treatment; triple negative breast cancer; TUMOR-INFILTRATING LYMPHOCYTES; STANDARD NEOADJUVANT CHEMOTHERAPY; SURGICAL ADJUVANT BREAST; PHASE-III TRIAL; OPEN-LABEL; PREOPERATIVE DOXORUBICIN; ANDROGEN RECEPTOR; PROGNOSTIC VALUE; PACLITAXEL; CYCLOPHOSPHAMIDE;

D O I：

10.1177/1758835920986749

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple negative breast cancer (TNBC) is a heterogeneous disease representing about 15% of all breast cancers. TNBC are usually high-grade histological tumors, and are generally more aggressive and difficult to treat due to the lack of targeted therapies available, and chemotherapy remains the standard treatment. There is a close relationship between pathological complete response after chemotherapy treatment and higher rates of disease-free survival and overall survival. In this review of systemic treatment in early triple negative breast cancer, our purpose is to analyze and compare different therapies, as well as to highlight the novelties of treatment in this breast cancer subtype.

引用

页数：18

共 97 条

[21] Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer [J].

Cyprian, Farhan S. ;

Akhtar, Saghir ;

Gatalica, Zoran ;

Vranic, Semir .

BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2019, 19 (03) :227-233

[22] TNFR2+TILs are significantly associated with improved survival in triple-negative breast cancer patients [J].

Dadiani, Maya ;

Necula, Daniela ;

Kahana-Edwin, Smadar ;

Oren, Nino ;

Baram, Tamir ;

Marin, Irina ;

Morzaev-Sulzbach, Dana ;

Pavlovski, Anya ;

Balint-Lahat, Nora ;

Anafi, Liat ;

Wiemann, Stefan ;

Korner, Cindy ;

Gal-Yam, Einav Nili ;

Avivi, Camila ;

Kaufman, Bella ;

Barshack, Iris ;

Ben-Baruch, Adit .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (07) :1315-1326

[23] A phase-2 trial of neoadjuvant alpelisib and nab-paclitaxel in anthracycline refractory triple negative breast cancers with PIK3CA or PTEN alterations [J].

Damodaran, Senthil ;

Litton, Jennifer K. ;

Hess, Kenneth R. ;

Eppig, Colleen T. ;

Grzegorzewski, Krzysztof J. ;

Meric-Bernstam, Funda ;

Wistuba, Ignacio I. ;

White, Jason B. ;

Rauch, Gaiane M. ;

Candelaria, Rosalind P. ;

Adrada, Beatriz E. ;

Lim, Bora ;

Moulder, Stacy L. ;

Tripathy, Debu .

CANCER RESEARCH, 2020, 80 (04)

[24] Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group [J].

De Jong, V. M. T. ;

Wang, Y. ;

Opdam, M. ;

ter Hoeve, N. ;

Jozwiak, K. ;

Hauptmann, M. ;

Stathonikos, N. ;

Horlings, H. ;

Broeks, A. ;

Michiels, S. ;

van der Wall, E. ;

van Diest, P. ;

Siesling, S. ;

Schmidt, M. K. ;

Loi, S. ;

Kok, M. ;

Linn, S. ;

Salgado, R. F. ;

Dackus, G. .

ANNALS OF ONCOLOGY, 2020, 31 :S303-S303

[25] Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers [J].

Denkert, Carsten ;

von Minckwitz, Gunter ;

Brase, Jan C. ;

Sinn, Bruno V. ;

Gade, Stephan ;

Kronenwett, Ralf ;

Pfitzner, Berit M. ;

Salat, Christoph ;

Loi, Sherene ;

Schmitt, Wolfgang D. ;

Schem, Christian ;

Fisch, Karin ;

Darb-Esfahani, Silvia ;

Mehta, Keyur ;

Sotiriou, Christos ;

Wienert, Stephan ;

Klare, Peter ;

Andre, Fabrice ;

Klauschen, Frederick ;

Blohmer, Jens-Uwe ;

Krappmann, Kristin ;

Schmidt, Marcus ;

Tesch, Hans ;

Kuemmel, Sherko ;

Sinn, Peter ;

Jackisch, Christian ;

Dietel, Manfred ;

Reimer, Toralf ;

Untch, Michael ;

Loibl, Sibylle .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) :983-991

[26] Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer [J].

Dieci, Maria Vittoria ;

Radosevic-Robin, Nina ;

Fineberg, Susan ;

van den Eynden, Gert ;

Ternes, Nils ;

Penault-Llorca, Frederique ;

Pruneri, Giancarlo ;

D'Alfonso, Timothy M. ;

Demaria, Sandra ;

Castaneda, Carlos ;

Sanchez, Joselyn ;

Badve, Sunil ;

Michiels, Stefan ;

Bossuyt, Veerle ;

Rojo, Federico ;

Singh, Baljit ;

Nielsen, Torsten ;

Viale, Giuseppe ;

Kim, Seong-Rim ;

Hewitt, Stephen ;

Wienert, Stephan ;

Loibl, Sybille ;

Rimm, David ;

Symmans, Fraser ;

Denkert, Carsten ;

Adams, Sylvia ;

Loi, Sherene ;

Salgado, Roberto .

SEMINARS IN CANCER BIOLOGY, 2018, 52 :16-25

[27]

Dimitrova N., 2016, EUROPEAN GUIDELINES

[28]

Ditsch N, 2002, J CLIN ONCOL, V21

[29] Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An anglo-celtic cooperative oncology group study [J].

Evans, TRJ ;

Yellowlees, A ;

Foster, E ;

Earl, H ;

Cameron, DA ;

Hutcheon, AW ;

Coleman, RE ;

Perren, T ;

Gallagher, CJ ;

Quigley, M ;

Crown, J ;

Jones, AL ;

Highley, M ;

Robert, LMH ;

Mansi, JL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2988-2995

[30] GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD). [J].

Fasching, Peter A. ;

Jackisch, Christian ;

Rhiem, Kerstin ;

Schneeweiss, Andreas ;

Klare, Peter ;

Hanusch, Claus ;

Huober, Jens Bodo ;

Link, Theresa ;

Untch, Michael ;

Schmatloch, Sabine ;

Denkert, Carsten ;

Stefek, Andrea ;

Uleer, Christoph ;

Doering, Gabriele ;

Engels, Knut ;

Seither, Fenja ;

Blohmer, Jens Uwe ;

Loibl, Sibylle .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 6 7 8 9 10 →